Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
A new drug, daraxonrasib, has successfully targeted the KRAS mutation responsible for most pancreatic tumors, a challenge previously considered impossible. In a major trial, the treatment nearly doubled survival rates for patients with advanced pancreatic cancer and reduced the risk of death by 60%. This breakthrough offers a more effective and less toxic alternative to traditional chemotherapy. The drug works by inhibiting a protein involved in KRAS folding, allowing it to function as a precise tool rather than a broad-acting treatment.
Scientists developed a new drug, daraxonrasib, that targets a key protein in pancreatic cancer, nearly doubling survival rates in a major trial.
This breakthrough offers new hope for patients with advanced pancreatic cancer, a disease that has long had few effective treatments.
The story highlights progress in medical science and the potential for more precise, less harmful treatments that improve patient outcomes.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.